Thymosin Alpha 1
Thymosin Alpha 1 is supplied as a thymic-derived immune peptide for Toll-like-receptor and cytokine-signaling pathway research in dendritic-cell and T-cell models. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
Thymosin Alpha 1 in research
Thymosin Alpha 1 is supplied as a thymic-derived immune peptide for Toll-like-receptor and cytokine-signaling pathway research in dendritic-cell and T-cell models.
Immune-signaling, barrier, and inflammation-model research for laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for Thymosin Alpha 1 before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
5mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Thymosin Alpha 1 is a peptide that has garnered significant attention in the scientific community for its potential to enhance immune function. Derived from the thymus gland, it plays a crucial role in the body's natural defense mechanisms. Researchers are particularly interested in how this peptide can support immune regulation and improve the body's response to various challenges.
Studies suggest that Thymosin Alpha 1 can aid in promoting a balanced immune response, making it a subject of interest for those studying immune health and recovery. Its ability to potentially modulate immune activity has sparked numerous investigations and research efforts worldwide.
In the realm of peptide research, Thymosin Alpha 1 is valued for its role in supporting immune function and its potential applications across multiple disciplines. As research advances, this peptide continues to be a promising candidate for further exploration.
10mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Thymosin Alpha 1, a cutting-edge peptide, is at the forefront of immune system research. Derived from the thymus gland, it plays a vital role in the body's natural defense mechanisms. Scientists are particularly interested in Thymosin Alpha 1 for its potential to enhance immune response, making it a subject of extensive research. This peptide is being studied for its ability to regulate immune function, which may have implications in managing autoimmune disorders and infections.
Current research focuses on understanding how Thymosin Alpha 1 modulates immune pathways and its potential to support immune health. With its unique properties, this peptide is used extensively in laboratories to explore innovative solutions for immune-related challenges. By leveraging the power of Thymosin Alpha 1, researchers aim to unlock new insights into immune system behavior and potential therapeutic applications.
Thymosin Alpha 1 is available for research purposes, providing an invaluable tool for scientists seeking to advance the field of immunology. Its growing popularity in research circles underscores its significant potential and the promising avenues it may open in peptide science.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
Thymosin Alpha-1 (also called thymalfasin) is among the more extensively studied immunomodulatory peptides and has accumulated genuine human-trial data, distinguishing it from most research peptides. Under the brand name Zadaxin, it has been evaluated in controlled clinical trials, including randomized work in chronic hepatitis B and a multicenter sepsis trial reported by investigators in China (often referenced as the ETASS study), and it was investigated in observational studies and small trials during the COVID-19 pandemic. Investigators report it as generally well tolerated in these settings, though findings across indications are mixed and several studies are limited by size, region, or open-label design, so the overall human evidence base remains heterogeneous rather than conclusive. These statements describe published third-party research and are not a BioRegen efficacy claim.
In laboratory and animal research, Thymosin Alpha-1 is characterized as a synthetic 28-amino-acid peptide that researchers describe as modulating immune signaling, including effects reported on T-cell maturation, dendritic cell activity, and toll-like receptor pathways. Preclinical investigators have studied it as a candidate immune adjuvant and in models of infection and immune dysregulation. This reflects the preclinical literature and is not a BioRegen claim.
Outside of formal research, longevity forums, biohacker communities, and some mainstream and trade media coverage have discussed Thymosin Alpha-1 in the context of immune support, often referencing its Zadaxin program. Such discussion frequently outpaces and overstates the controlled evidence and should not be read as established. This is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
Thymosin Alpha-1, marketed as Zadaxin (thymalfasin), is approved in a number of countries outside the United States, including for chronic hepatitis B and as an immune adjuvant in certain jurisdictions, and it has been granted orphan-drug status in some regions for select indications. It is NOT approved by the US Food and Drug Administration, and no statement here should be taken as indicating US approval or endorsement of human use. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about Thymosin Alpha 1
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and Hormones , 2016. https://doi.org/10.1016/bs.vh.2016.04.003
- Espinar-Buitrago MS, et al. Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection. International Immunopharmacology , 2023. https://doi.org/10.1016/j.intimp.2023.111103